| abstract |
The present invention relates to a novel anti-C-MPL antibody and the use thereof and, more particularly, to an anti-C-MPL antibody having the effects of platelet production and increased number of platelets by means of megakaryocyte maturation in bone marrow, and the use thereof. The novel anti-C-MPL antibody (2R13) of the present invention has a longer half-life than an existing therapeutic formulation as a polymer material, and is advantageous in that the possibilities of autoantibody production and immunogenicity are lower as an antibody formulation. Further, the present invention increases the platelet count of a patient suffering from immune thrombocytopenia which induces chronic diseases or complications, and thus can be used as a therapeutic formulation for thrombocytopenia. |